Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 19/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22791494 | 1.00 | KHK (0.66) | KHKFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL22770679 | 0.94 | KHK (0.73) | KHK | |
| SCHEMBL22770682 | 0.89 | KHK (0.71) | KHK | |
| SCHEMBL22770607 | 0.89 | KHK (0.71) | KHK | |
| SCHEMBL22828663 | 0.88 | KHK (0.49) | KHKFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL29466182 | 0.87 | KHK (0.70) | KHKFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL22791426 | 0.87 | KHK (0.70) | KHKFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL28702332 | 0.87 | KHK (0.70) | KHKFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL22770629 | 0.85 | KHK (0.71) | KHK | |
| SCHEMBL22770648 | 0.85 | KHK (0.70) | KHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114008036-B | Disubstituted pyrazole compounds as ketohexokinase inhibitors | 伊莱利利公司 | 2025-01-17 | — | — | CN | disclosed |
| EP-3983404-B1 | DISUBSTITUTED PYRAZOLE COMPOUNDS AS KETOHEXOKINASE INHBITORS | LILLY CO ELI (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3983404-B1 | DISUBSTITUTED PYRAZOLE COMPOUNDS AS KETOHEXOKINASE INHBITORS | LILLY CO ELI (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3983404-A1 | DISUBSTITUTED PYRAZOLE COMPOUNDS AS KETOHEXOKINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114008036-A | Disubstituted pyrazole compounds as ketohexokinase inhibitors | 伊莱利利公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20220017496-A1 | DISUBSTITUTED PYRAZOLE COMPOUNDS | ELI LILLY AND COMPANY | 2022-01-20 | — | — | US | disclosed |
| US-11124500-B2 | Disubstituted pyrazole compounds | ELI LILLY AND COMPANY (US) | 2021-09-21 | — | — | US | disclosed |
| WO-2020257171-A1 | DISUBSTITUTED PYRAZOLE COMPOUNDS AS KETOHEXOKINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200392118-A1 | DISUBSTITUTED PYRAZOLE COMPOUNDS | ELI LILLY AND COMPANY | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124500-B2 | Disubstituted pyrazole compounds | SLC5A2, SLC5A1, GOT2 | KHK 91/4885FGFR1 266/4885FGFR2 587/4885 |
| US-20200392118-A1 | DISUBSTITUTED PYRAZOLE COMPOUNDS | SLC5A2, SLC5A1, GOT2 | KHK 91/4885FGFR1 266/4885FGFR2 587/4885 |
| US-20220017496-A1 | DISUBSTITUTED PYRAZOLE COMPOUNDS | SLC5A2, SLC5A1, GOT2 | KHK 93/4885FGFR1 336/4885FGFR2 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.